Neurocrine Biosciences | NBIX - Debt

Stock Price
158.42
Daily Change
-0.63 -0.40%
Monthly
23.37%
Yearly
30.90%
Q2 Forecast
155.24

Neurocrine Biosciences reported $406.2M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amgen USD 54.6B 17M Dec/2025
Biogen USD 6.56B 275.1M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Cytokinetics USD 1.29B 4.48M Mar/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Exelixis USD 169.54M 3.5M Mar/2026
Gilead Sciences USD 24.94B 5M Dec/2025
Halozyme Therapeutics USD 2.14B 631.87M Dec/2025
Incyte USD 39.43M 982K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Prothena USD 9.08M 699K Sep/2025
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Repligen USD 546.58M 4.37M Mar/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Teva Pharmaceutical Industries USD 17.09B 21M Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026
Xoma USD 120.79M 3.27M Jun/2024